TuHURA Biosciences CEO to Present Phase 3 Oncology Pipeline at H.C. Wainwright BioConnect Conference
SHERIDAN, WYOMING - May 13, 2026 - TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy, has confirmed that President and Chief Executive Officer James A. Bianco, M.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City on May 19, 2026, at 2:00 pm ET. The appearance gives institutional investors and sector analysts direct access to leadership at a moment when TuHURA is running an active Phase 3 registration trial and advancing two additional pipeline programs. For stakeholders tracking immuno-oncology development timelines and clinical positioning, the session represents a structured opportunity to assess the company's near-term milestones.